Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

16.89 +0.91 (+5.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,007,372
Open 16.11
Bid (Size) 16.61 (1)
Ask (Size) 16.90 (14)
Prev. Close 15.98
Today's Range 16.08 - 16.91
52wk Range 8.030 - 17.75
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors. 
Via Chartmill
Arcutis (ARQT) Q2 Revenue Soars 164%
Via The Motley Fool

Performance

YTD
+16.0%
+16.0%
1 Month
+9.7%
+9.7%
3 Month
+23.9%
+23.9%
6 Month
+37.2%
+37.2%
1 Year
+76.3%
+76.3%

More News

Read More
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected
Via Chartmill
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis
Via Benzinga
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Analyst Expectations For Arcutis Biotherapeutics's Future
Via Benzinga
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick?
Via Chartmill
Arcutis Announces Chief Financial Officer Transition
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews
Via Benzinga
Arcutis and Padagis Agree to Stay Patent Lawsuit
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move
Via Talk Markets
Topics Stocks Stocks / Equities
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy?
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Via Benzinga
What's Going On With Arcutis Biotherapeutics Stock Monday?
Via Benzinga

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
The current price of Arcutis Biotherapeutics, Inc. - Common stock is 16.89
When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 08/15/25 04:00 PM ET
What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 848.58M
How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
Arcutis Biotherapeutics, Inc. - Common stock has 849M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.